News & Updates

Show Multimedia Only

Continuous positive airway pressure may reverse metabolic syndrome

24 Jan 2022

Obstructive sleep apnoea (OSA) treatment with continuous positive airway pressure (CPAP) has the potential to resolve metabolic syndrome in adult patients, according to data from the TREATOSA-MS study.

24 Jan 2022

Omicron: A harbinger of the end of COVID-19 pandemic?

23 Jan 2022 by

During the recent Omicron-driven wave of SARS-CoV-2 infection, there appears to be less severe COVID-19 disease compared with the previous wave driven by Delta, according to studies from South Africa — suggesting that Omicron may be a milder variant than its predecessors.

23 Jan 2022

Metabolic syndrome linked to greater COVID-19 severity

21 Jan 2022 by

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

21 Jan 2022

Aspirin does not cut death risk in hospitalized COVID-19 patients

20 Jan 2022 by

Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.

20 Jan 2022

Which factors set off TB recurrence?

20 Jan 2022

Recurrence interval is associated with the endogenous reactivation of tuberculosis (TB), according to the results of a meta-analysis. On the other hand, infection with Beijing family strains, coinfection with HIV, imprisonment, and immigration contribute to an increased risk of exogenous TB reinfection.

20 Jan 2022

DVT risk not raised after COVID-19 vaccination

19 Jan 2022 by

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

19 Jan 2022

Early remdesivir treatment lowers risk of COVID-19 progression

19 Jan 2022 by

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

19 Jan 2022

CATALYST sparks signals favouring namilumab for COVID-19

19 Jan 2022 by

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

19 Jan 2022

Asians bare unique genetic profile of KRAS-mutated NSCLC

19 Jan 2022 by

Nonsmall cell lung cancer (NSCLC) with mutations in the KRAS gene show a unique genetic and clinical profile in Asian patients relative to Western counterparts, according to a recent study.

19 Jan 2022

Fluvoxamine may prevent COVID-19 hospitalization

18 Jan 2022 by

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

18 Jan 2022

News & Updates

Showing Respirology articles

Showing

Specialty:

Continuous positive airway pressure may reverse metabolic syndrome

Omicron: A harbinger of the end of COVID-19 pandemic?

Metabolic syndrome linked to greater COVID-19 severity

Aspirin does not cut death risk in hospitalized COVID-19 patients

Which factors set off TB recurrence?

DVT risk not raised after COVID-19 vaccination

Early remdesivir treatment lowers risk of COVID-19 progression

CATALYST sparks signals favouring namilumab for COVID-19

Asians bare unique genetic profile of KRAS-mutated NSCLC

Fluvoxamine may prevent COVID-19 hospitalization